Moreover, the 36-month beta value for CATX is 1.11. Analysts have varying opinions on the stock, with 10 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for CATX is 53.94M and currently, short sellers hold a 9.76% of that float. On May 15, 2025, CATX’s average trading volume was 711.68K shares.
CATX) stock’s latest price update
Perspective Therapeutics Inc (AMEX: CATX)’s stock price has dropped by -15.29 in relation to previous closing price of 2.55. Nevertheless, the company has seen a loss of -8.09% in its stock price over the last five trading days. globenewswire.com reported 2025-05-12 that SEATTLE, May 12, 2025 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, today provided a business update and announced results for the quarter ended March 31, 2025.
CATX’s Market Performance
Perspective Therapeutics Inc (CATX) has seen a -8.09% fall in stock performance for the week, with a 5.37% gain in the past month and a -28.71% plunge in the past quarter. The volatility ratio for the week is 11.76%, and the volatility levels for the past 30 days are at 8.60% for CATX. The simple moving average for the past 20 days is -6.80% for CATX’s stock, with a -68.97% simple moving average for the past 200 days.
Analysts’ Opinion of CATX
Many brokerage firms have already submitted their reports for CATX stocks, with H.C. Wainwright repeating the rating for CATX by listing it as a “Buy.” The predicted price for CATX in the upcoming period, according to H.C. Wainwright is $10 based on the research report published on March 13, 2025 of the current year 2025.
Scotiabank, on the other hand, stated in their research note that they expect to see CATX reach a price target of $15. The rating they have provided for CATX stocks is “Sector Outperform” according to the report published on March 07th, 2025.
BofA Securities gave a rating of “Neutral” to CATX, setting the target price at $5 in the report published on November 25th of the previous year.
CATX Trading at -5.71% from the 50-Day Moving Average
After a stumble in the market that brought CATX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -88.66% of loss for the given period.
Volatility was left at 8.60%, however, over the last 30 days, the volatility rate increased by 11.76%, as shares surge +3.35% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.09% lower at present.
During the last 5 trading sessions, CATX fell by -8.09%, which changed the moving average for the period of 200-days by -84.23% in comparison to the 20-day moving average, which settled at $2.32. In addition, Perspective Therapeutics Inc saw -32.29% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CATX starting from Spoor Johan M., who purchase 22,026 shares at the price of $2.24 back on Mar 28 ’25. After this action, Spoor Johan M. now owns 59,383 shares of Perspective Therapeutics Inc, valued at $49,384 using the latest closing price.
Spoor Johan M., the Chief Executive Officer of Perspective Therapeutics Inc, purchase 4,650 shares at $2.21 during a trade that took place back on Mar 28 ’25, which means that Spoor Johan M. is holding 4,650 shares at $10,288 based on the most recent closing price.
Stock Fundamentals for CATX
The total capital return value is set at -0.28. Equity return is now at value -32.92, with -27.87 for asset returns.
Based on Perspective Therapeutics Inc (CATX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -4.5. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -1893.46.
Currently, EBITDA for the company is 10.46 million with net debt to EBITDA at 0.71. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.02.
Conclusion
To wrap up, the performance of Perspective Therapeutics Inc (CATX) has been bad in recent times. The stock has received a bullish of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
